# Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Study · id `cardio:ct-nct01327846` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01327846](<https://clinicaltrials.gov/study/NCT01327846>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01327846

Browse, organ or system: Heart; Blood vessels; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 10066 participants.

## Technical summary

Registry record NCT01327846. Randomized; triple masking; primary purpose treatment. Start 2011-04-11 (actual); primary completion 2017-03-28 (actual). Results posted on 2020-01-22.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 10066 participants (enrolled count; ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Started: 2011-04-11 (actual) (ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Primary completion: 2017-03-28 (actual) (ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Completion: 2019-04-14 (actual) (ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Results first posted: 2020-01-22 (ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Estonia; Germany; Greece; Guatemala; Hungary; Iceland; India; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Norway; Peru; Poland; Puerto Rico; Romania; Russia; Serbia; Slovakia; Slovenia; South Africa; South Korea; Sweden; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT01327846, source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01327846-2020-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
- Acronym: CANTOS
- Condition: Atherosclerosis
- Intervention (Drug): Canakinumab
- Intervention (Drug): Placebo
- Intervention (Drug): Standard of care
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (`cardio:pubmed-28845751`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (`cardio:pubmed-28855077`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (`cardio:pubmed-29544870`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (`cardio:pubmed-29793629`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) (`cardio:pubmed-30165610`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial (`cardio:pubmed-30242335`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure (`cardio:pubmed-30586730`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS (`cardio:pubmed-31884854`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial (`cardio:pubmed-32203978`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis (`cardio:pubmed-31504417`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial (`cardio:pubmed-32744862`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial (`cardio:pubmed-33004131`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial (`cardio:pubmed-35385050`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial (`cardio:pubmed-37934948`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial (`cardio:pubmed-38701435`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 398f36d8870b264b0dae4afe23698ece5afd02016a5bc29905fc351ac4990461
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
